---
title: "08:01 ETGinkgo Bioworks Announces Date of First Quarter 2026 Results Presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284764596.md"
description: "Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced a presentation and Q&A session to review its first quarter 2026 business performance. The event is scheduled for May 7, 2026, at 4:30 p.m. ET, following the market close. Details and a webcast link will be available on the company's investor relations website. Questions can be submitted via X or email. Ginkgo Bioworks specializes in engineering biology through autonomous laboratories and contract research services."
datetime: "2026-04-30T12:02:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284764596.md)
  - [en](https://longbridge.com/en/news/284764596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284764596.md)
---

# 08:01 ETGinkgo Bioworks Announces Date of First Quarter 2026 Results Presentation

_Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026_

, /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET.

The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.

To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to \[email protected\].

**About Ginkgo Bioworks  
**Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo\_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

**Ginkgo Bioworks Contacts:**

**INVESTOR CONTACT:**

\[email protected\]

**MEDIA CONTACT:**

\[email protected\]

SOURCE Ginkgo Bioworks

### Related Stocks

- [DNABW.US](https://longbridge.com/en/quote/DNABW.US.md)
- [DNA.US](https://longbridge.com/en/quote/DNA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Precision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up](https://longbridge.com/en/news/287737111.md)
- [Outlook Therapeutics Wins FDA Appeal For NAMD Therapy; Stock Up](https://longbridge.com/en/news/287640138.md)
- [Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B](https://longbridge.com/en/news/287774756.md)
- [BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment](https://longbridge.com/en/news/287634369.md)
- [BUZZ-Q32 Bio soars after $55 mln equity raise at a premium](https://longbridge.com/en/news/287771888.md)